Income statement, balance sheet and cash flow statement for the last 9 fiscal years, taken from the XBRL data IDEAYA Biosciences, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2017
FY2019
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
0
19.5
27.9
50.9
23.4
7
219
Research and development
12.4
31.7
34.3
39.7
58.2
89.5
130
295
315
General and administrative
2.05
4.67
9.95
15.2
20.1
23.9
28.3
39.3
63.3
Operating expenses
14.4
36.4
44.3
54.9
78.2
113
158
334
378
Operating income
-14.4
-36.4
-44.3
-35.3
-50.3
-62.5
-134
-327
-159
Interest income
0.15
1.99
2.29
Other non-operating income
2.43
2.07
2.3
0.85
0.51
3.85
21.5
52.5
45.6
Income tax
0
0
0
0
0
0
0
0
Net income
-11.9
-34.3
-42
-34.5
-49.8
-58.7
-113
-274
-114
EBITDA
-14
-35.5
-43
-34
-48.5
-60.4
-132
-325
-157
EPS, basic
-17.06
-35.92
-3.36
-1.40
-1.41
-1.42
-1.96
-3.36
-1.28
EPS, diluted
-17.06
-35.92
-3.36
-1.40
-1.41
-1.42
-1.96
-3.36
-1.28
Shares, basic (weighted)
0.7
0.96
12.5
24.7
35.3
41.4
57.5
81.7
88.5
Shares, diluted (weighted)
0.7
0.96
12.5
24.7
35.3
41.4
57.5
81.7
88.5
Balance sheet
FY2017
FY2019
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
5.96
20.5
34.1
72
92
68.6
157
84.4
113
Short-term investments
69.5
64.9
212
155
296
368
592
527
Receivables
1.88
1.1
0.21
0.02
0
Other current assets
0.71
2.7
3.14
3.12
5.41
7.5
13.4
21.4
Total current assets
90.7
102
289
251
370
533
690
667
Property, plant and equipment
5.15
4.64
4.27
4.76
6.51
6.16
8.97
8.22
Lease right-of-use assets
5.06
5.21
3.9
2.48
2.25
18.8
23.1
Long-term investments
1.53
0
121
8.32
107
406
410
Other non-current assets
0.05
0.02
0.08
0.29
0.1
0.03
Total assets
96.5
113
298
381
388
649
1,124
1,109
Accounts payable
1.42
0.71
0.95
2.1
4.28
6.6
15.4
17.6
Accrued liabilities
3.58
5.02
8.52
12.3
17
18.8
30.4
40.9
Deferred revenue
27.6
29
8.57
Total current liabilities
5.41
6.94
38.6
45.2
31.7
27.1
46.1
58.8
Lease liabilities
5.63
5.18
3.48
1.61
1.13
18.9
27.6
Other non-current liabilities
0.11
0.03
0.01
Total liabilities
7.1
12.6
100
79.8
38.5
28.2
64.9
86.4
Paid-in capital
1.6
193
325
479
588
969
1,681
1,757
Retained earnings
-50.5
-92.5
-127
-177
-235
-348
-623
-737
Other comprehensive income
-0.03
0.07
0.01
-0.71
-2.87
0.56
0.81
2.27
Shareholders' equity
-15.7
-48.9
100
198
302
349
621
1,059
1,023
Total equity
-15.7
-48.9
100
198
302
349
621
1,059
1,023
Total liabilities and equity
96.5
113
298
381
388
649
1,124
1,109
Shares outstanding
1.34
20.3
29.5
38.5
48.2
65
86.5
87.8
Cash flow statement
FY2017
FY2019
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-11.9
-34.3
-42
-34.5
-49.8
-58.7
-113
-274
-114
Depreciation and amortization
0.39
0.89
1.25
1.38
1.73
2.1
2.48
2.39
2.7
Stock-based compensation
0.14
0.95
2.17
3.61
8.24
11.6
18.5
34.7
46.1
Change in receivables
0
-1.88
0.77
0.89
0.19
0
0
Change in payables
0.25
0.32
-0.2
0.23
1.17
1.86
2.64
8.28
2.7
Cash from operations
-12.2
-27.6
-39.3
55.5
-55.8
-87.2
-115
-248
-71.1
Capital expenditures
-1.76
-1.71
-1.35
-0.49
-2.64
-3.44
-2.37
-3.86
-2.37
Purchases of investments
-13.5
-133
-88
-242
-315
-256
-596
-1,191
-608
Sales and maturities of investments
244
226
440
693
680
Cash from investing
-8.93
-63.2
2.27
-146
-69.7
-33.4
-158
-503
70
Stock issued
0.23
0.09
50.3
101
86
86.1
281
274
0
Cash from financing
17.5
105
50.6
129
145
97.2
363
678
29.8
Net change in cash
-3.66
14.6
13.6
38
20
-23.4
89
-72.6
28.7
Free cash flow
-14
-29.3
-40.7
55
-58.4
-90.6
-118
-251
-73.5
Interest paid
0.02
0.1
0.09
0.08
0.07
0.06
0.07
0.03
0
Income taxes paid
0
0
0
0
0
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $36.69 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-92.7%
Operating income / revenue.
EBITDA margin
-91.5%
EBITDA (operating income + depreciation and amortization) / revenue.
Net margin
-74.8%
Net income / revenue.
FCF margin
-48.6%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-47.7%
Cash from operations / revenue.
Return on equity (ROE)
-14.6%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-13.4%
Net income / average total assets.
Return on invested capital (ROIC)
-18.5%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
159.7%
Research and development expense / revenue.
Stock-based pay / revenue
23.6%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
0.9%
Capital expenditures / revenue.
D&A / revenue
1.2%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
3,024.0%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
62.5%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
62.1%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y
-3.4%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
43.0%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
38.8%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-1.3%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
41.9%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
30.0%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
8.3%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
28.8%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
29.1%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
10.5x
Current assets / current liabilities.
Quick ratio
10.0x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
10.0x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$2.54
Revenue / diluted weighted shares.
FCF per share
-$1.24
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$1.21
Cash from operations / diluted weighted shares.
Book value per share
$12.44
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
15.1x
Market cap / revenue.
P/B
2.95x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
2.95x
Market cap / tangible book value, when positive.
EV/Sales
11.6x
Enterprise value / revenue.
FCF yield
-3.2%
Free cash flow / market cap.
Earnings yield
-4.9%
Net income / market cap (the inverse of P/E).
What was IDEAYA Biosciences, Inc.'s revenue in fiscal 2025?
IDEAYA Biosciences, Inc. reported revenue of $218.7M for fiscal 2025, 3,024.4% higher than the year before.
Was IDEAYA Biosciences, Inc. profitable in fiscal 2025?
No. It reported a net loss of $113.7M.
How much free cash flow did IDEAYA Biosciences, Inc. generate in fiscal 2025?
Cash from operations of $71.1M minus capital expenditures of $2.4M left free cash flow of -$73.5M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.